Table 5.
Molecules for Therapy by Targeting TAMs.
| Molecules | Potential Mechanism | |
|---|---|---|
| Targeting the differentiation of TAMs | Ind. | Inhibiting the expression of PG [108] |
| tocilizumab | Blocking IL-6R [109] | |
| rIFN-γ | Simulating the role of IFN-γ to induce M2 to M1-like macrophages [16] | |
| SLP | Inducing T cells to inflow [110] | |
| Improvement in anti-tumor activity of TAMs | SPG | Inducing the cytotoxic activity of macrophage [111] |
| MCP-3 | Activating the phagocytic ability of macrophages [112] | |
| Pre-TNF | Increasing phagocytosis [113] | |
| bovine papilloma virus antibody | Inducing the cytotoxic activity of macrophage [114] | |
| PMMA | Stimulating TAMs to produce TNF-α [115] | |
| 6FN | Inducing TAMs to release anti-tumor cytokines [116] |
The table above shows the molecules used in therapy by targeting TAMs. Ind., Indomethacin; PG, prostaglandin; rIFN-γ, recombined interferon-γ; IL-6R, interleukin-6 receptor; SLP, synthetic long peptide; SPG, sizofiran; MCP-3, monocyte chemoattractant protein; pre-TNF, an uncleavable transmembrane form of tumor necrosis factor; PMMA, Poly methyl methacrylate; 6FN, 6-fluoro-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate.